CoChat

ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma

Open access
Ojha, Rani, Leli, Nektaria M., Onorati, Angelique, Piao, Shengfu, Verginadis, Ioannis I., Tameire, Feven, Rebecca, Vito W., Chude, Cynthia I., Murugan, Sengottuvelan, Fennelly, Colin, Noguera-Ortega, Estela, Chu, Charleen T., Liu, Shujing, Xu, Xiaowei, Krepler, Clemens, Xiao, Min, Xu, Wei, Wei, Zhi, Frederick, Dennie T., Boland, Genevieve, Mitchell, Tara C., Karakousis, Giorgos C., Schuchter, Lynn M., Flaherty, Keith T., Zhang, Gao, Herlyn, Meenhard, Koumenis, Constantinos, Amaravadi, Ravi K. · 2019 · Cancer Discovery
Cited by 91

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Resistance to BRAF and MEK inhibitors (BRAFi + MEKi) in BRAF-mutant tumors occurs through heterogeneous mechanisms, including ERK reactivation and autophagy. Little is known about the mechanisms by which ERK reactivation or autophagy is induced by BRAFi + MEKi. Here, we report that in BRAF-mutant melanoma cells, BRAFi + MEKi induced SEC61-dependent endoplasmic reticulum (ER) translocation of the MAPK pathway via GRP78 and KSR2. Inhibition of ER translocation prevented ERK reactivation and autophagy. Following ER translocation, ERK exited the ER and was rephosphorylated by PERK. Reactivated ERK phosphorylated ATF4, which activated cytoprotective autophagy. Upregulation of GRP78 and phosphorylation of ATF4 were detected in tumors of patients resistant to BRAFi + MEKi. ER translocation of the MAPK pathway was demonstrated in therapy-resistant patient-derived xenografts. Expression of a dominant-negative ATF4 mutant conferred sensitivity to BRAFi + MEKi in vivo. This mechanism reconciles two major targeted therapy resistance pathways and identifies druggable targets, whose inhibition would likely enhance the response to BRAFi + MEKi. Significance: ERK reactivation and autophagy are considered distinct resistance pathways to BRAF + MEK inhibition (BRAFi + MEKi) in BRAFV600E cancers. Here, we report BRAFi + MEKi–induced ER translocation of the MAPK pathway is necessary for ERK reactivation, which drives autophagy. The ER translocation mechanism is a major druggable driver of resistance to targeted therapy. This article is highlighted in the In This Issue feature, p. 305

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-18-0348

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 91

Metadata

Authors
Ojha, R., Leli, N. M., Onorati, A., Piao, S., Verginadis, I. I., Tameire, F., Rebecca, V. W., Chude, C. I., Murugan, S., Fennelly, C., Noguera-Ortega, E., Chu, C. T., Liu, S., Xu, X., Krepler, C., Xiao, M., Xu, W., Wei, Z., Frederick, D. T., Boland, G., Mitchell, T. C., Karakousis, G. C., Schuchter, L. M., Flaherty, K. T., Zhang, G., Herlyn, M., Koumenis, C., & Amaravadi, R. K.
Venue
Cancer Discovery
Published
2019-03-01
Volume
9
Issue
3
Pages
396-415
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2905390578
Cited by
91
References
13
FWCI
3.14
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. https://app.cochat.ai/papers/10.1158/2159-8290.cd-18-0348
The paper
Ojha, R., Leli, N. M., Onorati, A., Piao, S., Verginadis, I. I., Tameire, F., Rebecca, V. W., Chude, C. I., Murugan, S., Fennelly, C., Noguera-Ortega, E., Chu, C. T., Liu, S., Xu, X., Krepler, C., Xiao, M., Xu, W., Wei, Z., Frederick, D. T., . . . Amaravadi, R. K. (2019). ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-18-0348

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.